Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Alone vs Concurrent Chemoradiotherapy After GP Induction in Locally Advanced Nasopharyngeal Carcinoma
ChiCTR2100049340Phase 3Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100049340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049340.